ARTICLE | Finance
Epigenetics double-dip
Why Atlas decided time was right to form epigenetics company Rodin
July 1, 2013 7:00 AM UTC
Atlas Venture's newest startup and second dip into epigenetics, Rodin Therapeutics Inc., is developing small molecule epigenetic modulators to treat Alzheimer's disease and other CNS disorders.
The VC firm has been interested in epigenetic approaches to neurologic disorders for about five years. Atlas contemplated creating a startup in 2008 and 2010, but didn't know where it would find modulators that could specifically and selectively bind to the undisclosed targets of interest, according to Partner and acting Rodin CEO Bruce Booth...